Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

631 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Mahaffey KW, Stevens SR, White HD, Nessel CC, Goodman SG, Piccini JP, Patel MR, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Califf RM, Fox KA, Breithardt G; ROCKET AF Investigators. Mahaffey KW, et al. Eur Heart J. 2014 Jan;35(4):233-41. doi: 10.1093/eurheartj/eht428. Epub 2013 Oct 15. Eur Heart J. 2014. PMID: 24132190 Free PMC article. Clinical Trial.
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Mahaffey KW, et al. Am Heart J. 2002 Feb;143(2):242-8. doi: 10.1067/mhj.2002.120145. Am Heart J. 2002. PMID: 11835026
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ. Mukherjee D, et al. Among authors: mahaffey kw. Am Heart J. 2002 Dec;144(6):995-1002. doi: 10.1067/mhj.2002.126118. Am Heart J. 2002. PMID: 12486423 Clinical Trial.
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
Kaul P, Newby LK, Fu Y, Hasselblad V, Mahaffey KW, Christenson RH, Harrington RA, Ohman EM, Topol EJ, Califf RM, Van de Werf F, Armstrong PW; PARAGON-B Investigators. Kaul P, et al. Among authors: mahaffey kw. J Am Coll Cardiol. 2003 Feb 5;41(3):371-80. doi: 10.1016/s0735-1097(02)02824-3. J Am Coll Cardiol. 2003. PMID: 12575962 Free article. Clinical Trial.
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
Kandzari DE, Granger CB, Simoons ML, White HD, Simes J, Mahaffey KW, Gore J, Weaver WD, Longstreth WT Jr, Stebbins A, Lee KL, Califf RM, Topol EJ; Global Utilization of Streptokinase and tPA for Occluded Arteries-I Investigators. Kandzari DE, et al. Among authors: mahaffey kw. Am J Cardiol. 2004 Feb 15;93(4):458-61. doi: 10.1016/j.amjcard.2003.10.043. Am J Cardiol. 2004. PMID: 14969623
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Ferguson JJ, et al. Among authors: mahaffey kw. JAMA. 2004 Jul 7;292(1):45-54. doi: 10.1001/jama.292.1.45. JAMA. 2004. PMID: 15238590 Clinical Trial.
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Petersen JL, et al. Among authors: mahaffey kw. JAMA. 2004 Jul 7;292(1):89-96. doi: 10.1001/jama.292.1.89. JAMA. 2004. PMID: 15238596 Review.
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ; SYNERGY Library. Petersen JL, et al. Among authors: mahaffey kw. Am Heart J. 2004 Aug;148(2):269-76. doi: 10.1016/j.ahj.2004.03.022. Am Heart J. 2004. PMID: 15308996 Clinical Trial.
631 results